09:50 AM EDT, 04/01/2024 (MT Newswires) -- Incyte ( INCY ) said Monday that it has partnered with China Medical System Holdings' dermatology medical aesthetic unit, CMS Skinhealth, to develop and commercialize Incyte's ( INCY ) povorcitinib to treat certain skin autoimmune and inflammation disorders.

Incyte ( INCY ) said it will receive an unspecified upfront payment from CMS, which will also make additional payments as povorcitinib reaches certain development and commercial milestones.

Incyte ( INCY ) said it is also eligible for royalties based on future net sales of povorcitinib in mainland China, Hong Kong, Macao, Taiwan and eleven other countries in southeast Asia.

The deal also includes a non-exclusive license for CMS to manufacture povorcitinib throughout its commercial territory.

Povorcitinib currently is in late-stage clinical trials as a potential treatment for non-segmental vitiligo and hidradenitis suppurativa in several countries outside of China. Mid-stage clinical studies are also underway in patients with prurigo nodularis, asthma and chornic spontaneous urticaria.

Price: 56.74, Change: -0.23, Percent Change: -0.40